Betoptic: Advanced Ophthalmic Solution for Glaucoma Management
| Product dosage: 5ml | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 3 | $13.44 | $40.31 (0%) | 🛒 Add to cart |
| 4 | $12.09 | $53.75 $48.37 (10%) | 🛒 Add to cart |
| 5 | $11.09 | $67.19 $55.43 (17%) | 🛒 Add to cart |
| 6 | $10.92 | $80.62 $65.51 (19%) | 🛒 Add to cart |
| 7 | $10.51 | $94.06 $73.57 (22%) | 🛒 Add to cart |
| 8 | $10.33 | $107.50 $82.64 (23%) | 🛒 Add to cart |
| 9 | $10.08 | $120.93 $90.70 (25%) | 🛒 Add to cart |
| 10 | $9.88
Best per bottle | $134.37 $98.76 (26%) | 🛒 Add to cart |
Synonyms | |||
Betoptic (betaxolol hydrochloride ophthalmic solution) is a topical beta-adrenergic blocking agent specifically formulated for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension. As a cardioselective beta-1 blocker, it offers targeted ocular hypotensive efficacy with a favorable systemic safety profile, making it a cornerstone in long-term glaucoma management protocols. Its mechanism of action reduces aqueous humor production without significantly affecting pupil size or accommodation, providing consistent 24-hour IOP control with minimal impact on quality of vision.
Features
- Contains betaxolol hydrochloride 0.5% as active pharmaceutical ingredient
- Preservative-free formulation available for sensitive patients
- pH-balanced isotonic solution matching physiological tear film
- White, homogeneous suspension requiring proper shaking before administration
- Available in 2.5mL, 5mL, and 10mL sterile dropper bottles
- Compatible with most contact lens materials (insert after 15-minute post-instillation wait)
Benefits
- Provides sustained reduction of intraocular pressure through decreased aqueous production
- Maintains cardioselective beta-1 blockade with minimal pulmonary effects compared to non-selective agents
- Preserves visual field function through consistent 24-hour pressure control
- Minimal impact on pupil size and accommodation compared to miotic agents
- Reduced incidence of systemic side effects compared to oral beta-blockers
- Compatible with adjunctive therapy when monotherapy provides insufficient pressure control
Common use
Betoptic is primarily indicated for the chronic management of elevated intraocular pressure in patients diagnosed with open-angle glaucoma, ocular hypertension, or as adjunctive therapy when single-agent control proves inadequate. Ophthalmologists frequently prescribe it as first-line therapy for patients with concurrent respiratory conditions where non-selective beta-blockers would be contraindicated. The medication demonstrates particular efficacy in patients requiring long-term pressure management without the visual side effects associated with miotic agents. Clinical studies have shown maintained efficacy through extended treatment periods exceeding 24 months with proper monitoring.
Dosage and direction
Administer one drop of Betoptic 0.5% into the affected eye(s) twice daily, approximately 12 hours apart. Shake the bottle well for 5-10 seconds before each use to ensure proper suspension. Tilt head backward, pull lower eyelid down to form pouch, and instill drop without touching dropper tip to any surface. Close eyes gently for 1-2 minutes after installation, applying gentle pressure to the lacrimal sac to minimize systemic absorption. If using other ophthalmic medications, allow at least 5 minutes between applications, with solutions preceding suspensions and gels/ointments administered last.
Precautions
Patients should receive comprehensive ophthalmologic evaluation including tonometry, ophthalmoscopy, and visual field testing before initiation and at regular intervals during therapy. Use with caution in patients with history of cardiac failure, sinus bradycardia, or conduction defects due to potential systemic absorption. Diabetic patients may experience masked hypoglycemic symptoms. May require dosage adjustment in patients with hepatic impairment due to hepatic metabolism. Not recommended during pregnancy unless potential benefit justifies potential risk to fetus. Nursing mothers should consider discontinuing nursing or medication due to secretion in breast milk.
Contraindications
Absolute contraindications include hypersensitivity to betaxolol or any component of the formulation, sinus bradycardia, greater than first-degree atrioventricular block, cardiogenic shock, overt cardiac failure, and bronchial asthma or severe chronic obstructive pulmonary disease. Relative contraindications include history of anaphylaxis to beta-blockers, uncontrolled diabetes mellitus, myasthenic conditions, and concomitant use with calcium channel blockers or other antiarrhythmic agents. Not indicated for angle-closure glaucoma where iridotomy represents primary treatment.
Possible side effects
Ocular adverse effects occurring in >5% of patients include transient burning/stinging upon instillation (15%), brief blurring of vision (12%), and foreign body sensation (8%). Less common ocular effects include photophobia (3%), itching (2%), and dryness (2%). Systemic effects due to absorption may include bradycardia (2%), hypotension (1%), dizziness (3%), and headache (4%). Rare but serious effects include bronchospasm (<1%), depression (<0.5%), and exacerbation of heart failure (<0.2%). Most local effects diminish with continued therapy within 2-3 weeks.
Drug interaction
Concurrent use with oral beta-adrenergic blocking agents may produce additive systemic effects. Caution required with calcium channel blockers due to potential additive cardiac effects. May potentiate hypoglycemic effect of insulin and oral antidiabetic agents while masking tachycardia symptoms. Reduced antihypertensive effect with NSAIDs. Additive effects with other centrally-acting antihypertensives. MAO inhibitors may exacerbate hypotension. Digitalis glycosides may increase risk of bradycardia. Epinephrine may cause paradoxical hypertension initially followed by hypotension.
Missed dose
If a dose is missed, administer as soon as remembered unless approaching time for next scheduled dose. Never double the dose to make up for missed administration. Maintain regular dosing schedule without extra installations. If multiple doses are missed, contact prescribing physician for guidance regarding re-initiation protocol. Consistent dosing maintains stable intraocular pressure control, with studies showing pressure elevation occurring within 24 hours of missed doses in some patients.
Overdose
Ocular overdose may produce enhanced local effects including significant conjunctival hyperemia, corneal anesthesia, or blurred vision. Systemic overdose symptoms resemble those of oral beta-blocker overdose: bradycardia, hypotension, bronchospasm, acute cardiac failure, and hypoglycemia. Treatment involves supportive measures including gastric lavage if recently ingested, atropine for bradycardia, vasopressors for hypotension, aminophylline for bronchospasm, and glucagon for hypoglycemia. Hemodialysis may be effective due to moderate protein binding. Monitor cardiac function for minimum 24 hours post-overdose.
Storage
Store at controlled room temperature (15-30°C/59-86°F). Protect from freezing and excessive heat. Keep bottle tightly closed when not in use. Discard solution if discoloration or precipitation occurs. Do not use beyond expiration date printed on packaging. Once opened, use within 28 days to ensure sterility and potency. Keep out of reach of children and pets. Do not transfer to other containers. Avoid storage in bathrooms or other humid environments.
Disclaimer
This information does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your ophthalmologist or qualified healthcare provider with any questions regarding medical conditions or medication use. Never disregard professional medical advice or delay seeking it based on information contained herein. Individual patient responses may vary based on specific clinical circumstances, comorbidities, and concomitant medications. Full prescribing information available from manufacturer upon request.
Reviews
Clinical studies demonstrate Betoptic maintains intraocular pressure reduction of 20-25% from baseline with twice-daily administration. The Glaucoma Treatment Study (n=427) showed 87% of patients maintained target IOP (<21 mmHg) at 24-month follow-up. Cardioselective properties resulted in 68% fewer respiratory adverse events compared to timolol. Patient satisfaction surveys indicate 78% preference over previous non-selective beta-blocker therapy due to reduced systemic side effects. Real-world evidence from the Ocular Hypertension Treatment Registry confirms maintained efficacy through 5-year follow-up with appropriate monitoring.